Home News About Us Contact Contributors Disclaimer Privacy Policy Help FAQ

Home
Search
Quick Search
Advanced
Fulltext
Browse
Collections
Persons
My eDoc
Session History
Login
Name:
Password:
Documentation
Help
Support Wiki
Direct access to
document ID:


          Institute: MPI für Herz- und Lungenforschung (W. G. Kerckhoff Institut)     Collection: Yearbook 2016     Display Documents



ID: 723982.0, MPI für Herz- und Lungenforschung (W. G. Kerckhoff Institut) / Yearbook 2016
5-HT2B receptor antagonists inhibit fibrosis and protect from RV heart failure
Authors:Janssen, W.; Schymura, Y.; Novoyatleva, T.; Kojonazarov, B.; Boehm, M.; Wietelmann, A.; Luitel, H.; Murmann, K.; Krompiec, D. R.; Tretyn, A.; Pullamsetti, S. S.; Weissmann, N.; Seeger, W.; Ghofrani, H. A.; Schermuly, R. T.
Date of Publication (YYYY-MM-DD):2015
Title of Journal:Biomed Res Int
Volume:2015
Start Page:438403
Audience:Not Specified
Abstract / Description:OBJECTIVE: The serotonin (5-HT) pathway was shown to play a role in pulmonary hypertension (PH), but its functions in right ventricular failure (RVF) remain poorly understood. The aim of the current study was to investigate the effects of Terguride (5-HT2A and 2B receptor antagonist) or SB204741 (5-HT2B receptor antagonist) on right heart function and structure upon pulmonary artery banding (PAB) in mice. METHODS: Seven days after PAB, mice were treated for 14 days with Terguride (0.2 mg/kg bid) or SB204741 (5 mg/kg day). Right heart function and remodeling were assessed by right heart catheterization, magnetic resonance imaging (MRI), and histomorphometric methods. Total secreted collagen content was determined in mouse cardiac fibroblasts isolated from RV tissues. RESULTS: Chronic treatment with Terguride or SB204741 reduced right ventricular fibrosis and showed improved heart function in mice after PAB. Moreover, 5-HT2B receptor antagonists diminished TGF-beta1 induced collagen synthesis of RV cardiac fibroblasts in vitro. CONCLUSION: 5-HT2B receptor antagonists reduce collagen deposition, thereby inhibiting right ventricular fibrosis. Chronic treatment prevented the development and progression of pressure overload-induced RVF in mice. Thus, 5-HT2B receptor antagonists represent a valuable novel therapeutic approach for RVF.
Free Keywords:Animals; Endomyocardial Fibrosis/metabolism/prevention & control; Heart/*drug effects; Heart Failure/*metabolism; Hemodynamics/drug effects; Male; Mice; Mice, Inbred C57BL; Myocardium/chemistry/metabolism; Protective Agents/*pharmacology; Receptor, Serotonin, 5-HT2B/analysis/genetics/*metabolism; Serotonin 5-HT2 Receptor Antagonists/*pharmacology; Ventricular Dysfunction, Right/*metabolism
External Publication Status:published
Document Type:Article
Communicated by:n.n.
Affiliations:MPI für physiologische und klinische Forschung
External Affiliations:Max-Planck-Institute for Heart and Lung Research, Ludwigstrasse 43, 61231 Bad Nauheim, Germany. Universities of Giessen and Marburg Lung Centre (UGMLC), Aulweg 130, 35392 Giessen, Germany ; German Center for Lung Research (DZL), 35392 Giessen, Germany ; Max-Planck-Institute for Heart and Lung Research, Ludwigstrasse 43, 61231 Bad Nauheim, Germany.
Identifiers:ISSN:2314-6141 (Electronic) %R 10.1155/2015/438403
URL:http://www.ncbi.nlm.nih.gov/pubmed/25667920
The scope and number of records on eDoc is subject to the collection policies defined by each institute - see "info" button in the collection browse view.